Vinblastine Sulfate interactions
Checked as Vinblastine in this data source.
Full monograph for Vinblastine SulfateCheck it against another medicine
Medicines
263 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| ErythromycinLotionOral | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Thalidomide | Major | Synergy | Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism… | 20 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Tucatinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Voriconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are… | 41 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Alpelisib | Moderate | Excretion | Coadministration with alpelisib may theoretically increase the plasma concentrations of drugs that are substrates of organic anion transporter (OAT3)… | 5 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily… | 6 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Bendamustine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Bleomycin Sulfate | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or… | 4 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is… | 5 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in… | 6 sources — open the full entry |
| Cabazitaxel | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Cabozantinib | Moderate | Others | Based on in vitro inhibition data, coadministration with cabozantinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 2 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are… | 1 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
Conditions
Conditions in which Vinblastine Sulfate needs care, as documented in this source.
Bone Marrow Failure Disorders
MajorThe use of vinblastine is contraindicated in patients with significant granulocytopenia. Vinblastine induces dose-dependent leukopenia. Thrombocytopenia and anemia have been reported infrequently during vinblastine therapy. Therapy with vinblastine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.
1 source
- "Product Information. Velban (vinblastine)." Lilly, Eli and Company (2001):
Infections
MajorThe use of vinblastine is contraindicated in patients with known infectious diseases. Vinblastine can induce myelosuppression. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vinblastine. Close clinical monitoring of hematopoietic function is recommended. Vinblastine should not be used in patients with neutrophil counts below 1000/mm3.
1 source
- "Product Information. Velban (vinblastine)." Lilly, Eli and Company (2001):
Respiratory Insufficiency
MajorAcute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids. These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose. Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction. Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids. In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.
3 sources
- "Product Information. Velban (vinblastine)." Lilly, Eli and Company (2001):
- "Product Information. Oncovin (vincristine)." Lilly, Eli and Company (2001):
- "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome (2001):
Liver Diseases
ModerateVinblastine is metabolized by the liver and eliminated primarily via biliary excretion. Patients with hepatic impairment may be at increased risk for toxicity associated with vinblastine therapy. Therapy with vinblastine should be administered cautiously in patients with compromised hepatic function.
1 source
- "Product Information. Velban (vinblastine)." Lilly, Eli and Company (2001):